Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Weiqing Chen et al.|Signal Transduction and Targeted Therapy|2025Cited by 20
ARHGEF28 gene exon 6/intron 6 junction mutations in Chinese amyotrophic lateral sclerosis cohortYan Ma, Dongsheng Fan, Lu Tang et al.|Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration|2014Cited by 19